Shattuck Labs (STTK) stock

Antibody treatments , market cap $451M

Antibody treatments

Worth $451M

$4.85

-2.81%

As of Tuesday's close · Live for Pro members at the open

Why is STTK down?

Down 13% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and pharma stocks a median 6%.

Its Nov 5 results: net loss widened to $25.2M, from $10.1M a year before; research and development expenses were $21.6M, from $7.6M. It fell 13% on Nov 5.

Sources: Price history, Nov 5, 2026; Company release, Nov 5, 2026

−2Dilution 153.8% more shares outstanding than a year ago

Tell me next time STTK moves

Free account, no card. An optional alert when STTK moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →1 more reason why STTK fell on Nov 5, from its filings, with the other side, how the business stands, the timeline, and its peers, for Pro members.

Why STTK still beats the market over a year

Up 164% over the year to Nov 9 while the S&P 500 rose 12%; down 13% on Nov 5.

2 reasons, from its filings, with the timeline, for Pro members.

Quality Score

-3

Poor

In its industry

#74of 90

Pharma

Checks firing

3of 14

Choppy

From 52-week high

-41.8%

under its best in a year

STTK's Quality Score was unchanged on Tue, Nov 10, at -3.

Follow STTK's trial news. Pro members can get an alert when Shattuck Labs files news, and see its trials, share raises, and its CEO's filings.

Get an alert when STTK files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“…clinical trial of SL-325 in hidradenitis suppurativa; trial initiation expected in the fourth quarter of 2026…”Trial start · SEC filing · Nov 5

Key facts on STTK

Key facts on STTK
Holding it back	153.8% more shares than a year ago
Latest filing	8-K, Nov 5 Reported its quarterly results

1 more reason behind STTK's -3, free with an account →5 more reasons behind STTK's -3, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

STTK catalysts

Coming up

After its last 4 reports it closed -2.7% on average, higher 2 of 4 times.

4 past catalysts since 2026, with sizes and sources, for Pro members.

What's next for STTK, and how long its cash lasts

Next step the company has named

Q4 2026“– Announced RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in hidradenitis suppurativa; trial initiation expected in the fourth quarter of 2026 –”Trial start · SEC filing · Nov 5

What it means: when a trial begins, or reaches the stage the company named.

Lead program: SL-325
Another trial: RECEPTIVE-CD1Phase 2 · Recruiting · 232 people · main data estimated Jul 2028 · NCT07753850

1 more trial, 2 more milestones and 30 filings, for Pro members.

Cash runway

The company says its cash lasts into 2029 (8-K, Nov 5).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Jan 13, 2026)
At-the-market share sales program (424B5, filed Jan 22, 2026)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

Chief Technical Officer Abhinav A. Shukla sold 410 shares on Jul 2, under a planned sale. 5 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Taylor Schreiber buys or sells

For Pro members: every trade, and Taylor Schreiber’s 12 filings and quotes.

Get an alert when STTK files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How STTK ranks in Pharma

STTK is #74 of 90 by Quality Score.

How STTK ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	10/14	23
2	LLYEli Lilly	8/14	21
3	PFEPfizer	6/14	17
	SLSSELLAS Life Sciences		Open for its score
	SNYSanofi		Open for its score
	SUPNSupernus		Open for its score
	SVRASavara		Open for its score
74	STTKShattuck Labs	3/14	-3

When does STTK report earnings, and what happens after?

Expected to report Thu Mar 11, before the open (in 121 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What STTK reported on Nov 5, 2026

The quarter

A loss of $0.14 a share, from $0.14.

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

STTK's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
Into 2029
Cash runway	into 2029

Figures as filed (SEC filing, Nov 5)

The numbers

Market value: $451M; today
Sales: $0; down 100% on the year

Its share count grew 18% a year over 3 years.

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on STTK: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 4

+7.8%-6.3%+0.6%-12.8%

Mar 5May 7Aug 11Nov 5

Reported	When	Gap	Reaction	5 days
Nov 5, 2026Before open	Before open	-0.8%	-12.8%	not yet
Aug 11, 2026Before open	Before open	+0.6%	+0.6%	+3.5%
May 7, 2026Before open	Before open	-0.5%	-6.3%	+1.1%
Mar 5, 2026Before open	Before open	-3.6%	+7.8%	+24.3%

STTK closed higher after 2 of its last 4 reports.

STTK sales and profit by year

Sales and profit by year

Sales grew in four of the last six years, to $1M in 2025. It lost money in each of the seven years.

STTK has 3 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on STTK, and all 14 on every stock.Get in free →

STTK RSI today: 38.6, below its 50-day and 200-day averages

Not scored

RSI 38.6, MACD below signal, below both averages. Not scored.13 readings

The deep dive on STTK

What it does and how it makes money2 findingsAn operating loss of $51.5M in fiscal 2025, on $1.00M of sales.Annual report, filed Mar 5, 2026
What changed in its filings3 findingsA new heading in its "Risk Factors" this year: "SL-325 is in early stages of clinical development and our other product candidates are in preclinical stages of development, and any of our product candidates may fail in development or suffer delays. We depend on the successful initiation and completion of …" (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Mar 5, 2026, against the one of Mar 27, 2025
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades STTK, for Pro members

5 more findings on STTK, each with its source, for Pro members.

STTK share count over time

Shares: 2.5 times the count a year ago (to Sep 30).

Shares of STTK outstanding, as filed
Shares outstanding	As of
101.8M	Nov 2, 2026
100.4M	Aug 7, 2026
76.7M	Apr 30, 2026
71.6M	Feb 26, 2026

Offerings, shelves, and splits of STTK, from its filings
From its filings	Filed
Raised $43.5M in a sale of shares, about 10% of its market value	Jun 11, 2026
Set up an at-the-market program for up to $75M of shares, about 17% of its market value	Jan 22, 2026
Registered shares for a later sale (S-3)	Jan 13, 2026
Registered shares for a later sale (S-3)	Sep 18, 2025

STTK insider trades

One insider bought $250K across 1 filing in the last 6 months. No open-⁠market sales on record. The newest:

BuyClay B. Siegall$250KDirectorat $4.00 on Jun 9, filed Jun 11

BuyClay B. SiegallDirector$250Kat $4.00 on Jun 9, filed Jun 11

STTK's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Taylor SchreiberChief Executive Officer · no trades on file
Andrew R. NeillChief Financial Officer · no trades on file
Abhinav A. ShuklaChief Technical Officer · 4 trades
Arundathy N. PanditeChief Medical Officer · 2 trades
Casi DeYoungChief Business Officer · no trades on file
Stephen StoutOfficer · no trades on file
Clay B. SiegallDirector · 1 trade
Clay B. SiegallDirector · no trades on file

See insider trades by person

Which ETFs hold STTK?

In ETFs: STTK is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Shattuck Labs

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

40 employeesAustin, TXshattucklabs.com

What Shattuck Labs says it competes with

“The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”

From its annual report, SEC filing · Mar 5, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on STTK and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn STTK's score around: 8 things
8 more filings explained, a plain line each
5 more things pulling STTK's score down

BreakawayJun 11Clay B. Siegall bought STTK$250K at $4.00, filed Jun 11

Alerts are optional.

See STTK's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: STTK's Quality Score is -3 (Poor), #74 of 90 in Pharma. Insiders bought $250K in the last 6 months (Form 4).

What does STTK's Quality Score say?

STTK scores -3 today, which Breakaway calls Poor. It is #74 of 90 in Pharma by Quality Score, with 3 of 14 chart checks firing. Down 13% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and pharma stocks a median 6%. Shares: 2.5 times the count a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is STTK's Quality Score?

STTK scores -3 today, which Breakaway calls Poor (below zero). That is #74 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind STTK's -3.

Are insiders buying STTK?

One insider bought $250K across 1 filing in the last 6 months. No open-⁠market sales on record. The newest is Clay B. Siegall, Director, who bought $250K on Jun 9.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.